Histone Deacetylase Inhibitor (HDACi) Suberoylanilide Hydroxamic Acid (SAHA)-mediated Correction of α1-Antitrypsin Deficiency

Received for publication, July 25, 2012, and in revised form, September 12, 2012. Published, JBC Papers in Press, September 20, 2012, DOI 10.1074/jbc.M112.404707

Marion Boucheareilh, Darren M. Hutt, Patricia Szajner, Terence R. Flotte, and William E. Balch

From the Department of Cell Biology, The Skaggs Institute for Chemical Biology, Department of Chemical Physiology, and the Institute for Childhood and Neglected Diseases, The Scripps Research Institute, La Jolla, California 92037 and the Department of Pediatrics and Gene Therapy Center UMass Medical School, Worcester, Massachusetts 01655

Background: α1-Antitrypsin (α1AT) deficiency (α1ATD) is a consequence of defective folding, trafficking, and secretion of α1AT.

Results: SAHA restores the secretion of an active form of Z-α1AT in part through a calnexin- and HDAC7-dependent mechanism(s).

Conclusion: SAHA may represent a potential therapeutic approach for α1ATD.

Significance: SAHA is a regulator of the proteostasis biology of Z-α1AT, favoring export of a functional form to serum.

α1-Antitrypsin (α1AT) deficiency (α1ATD) is a consequence of defective folding, trafficking, and secretion of α1AT in response to a defect in its interaction with the endoplasmic reticulum proteostasis machineries. The most common and severe form of α1ATD is caused by the Z-variant and is characterized by the accumulation of α1AT polymers in the endoplasmic reticulum of the liver leading to a severe reduction (>85%) of α1AT in the serum and its anti-protease activity in the lung. In this organ α1AT is critical for ensuring tissue integrity by inhibiting neutrophil elastase, a protease that degrades elastin. Given the limited therapeutic options in α1ATD, a more detailed understanding of the folding and trafficking biology governing α1AT biogenesis and its response to small molecule regulators is required. Herein we report the correction of Z-α1AT secretion in response to treatment with the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA), acting in part through HDAC7 silencing and involving a calnexin-sensitive mechanism. SAHA-mediated correction restores Z-α1AT secretion and serpin activity to a level 50% that is observed for wild-type α1AT. These data suggest that HDAC activity can influence Z-α1AT protein traffic and that SAHA may represent a potential therapeutic approach for α1ATD and other protein misfolding diseases.

Proper protein folding is essential to maintain cellular function and organismal health. The pathways that generate and protect the fold collectively make up the proteostasis network (PN) (1), a complex system of chaperones, folding enzymes, and degradative components (2–9). The PN is controlled by numerous signaling pathways such as the unfolded protein response (10, 11) and the heat shock response (12, 13) as well as Ca2+-sensing signaling pathways (5), autophagy (14, 15), integrated oxidative stress and inflammatory signaling pathways (16–21), and the acetylation proteostasis system (22). The PN includes components required for folding both cytosolic proteins and those found within the exocytic compartments, such as the endoplasmic reticulum (ER). Genetic disorders, including missense mutations, alter polypeptide chain folding energetics (4, 23), often putting protein folding out of reach of the folding capacity of the prevailing PN, triggering misfolding disease (2, 5, 6, 9, 24–27).

We now appreciate that α1AT deficiency (α1ATD) is a disorder of proteostasis-mediated protein folding and trafficking pathways (2, 14, 22, 27–32). α1AT is a soluble 52-kDa glycoprotein and the most abundant member of the serine protease inhibitor (SERPIN) family in plasma. It is delivered to the lung where α1AT is critical to prevent degradation of elastin, a key component ensuring the maintenance of lung elasticity. α1AT is considered as a metastable protein that is produced and secreted primarily by hepatocytes, with a poorly characterized contribution from lung macrophages and type II lung alveolar cells (14, 27, 33). α1AT acts as an inhibitor of serine proteases such as human neutrophil elastase (HNE), cathepsin G, and proteinase-3 by capturing these proteins in an irreversible, higher molecular weight suicide complex through loop-sheet insertion and proteolytic cleavage (33–35).

The reduced serum concentration of α1AT is a universal characteristic of α1ATD, reflecting the failure of folding and trafficking of α1AT through the secretory pathway (14, 33, 35, 36). The most common causes of inherited α1ATD are the Z- and S-variants of α1AT, which are caused by the E342K and E264V mutations, respectively, with the homozygous Z-α1AT

*This work was supported, in whole or in part, by National Institutes of Health Grants GM33301, GM42336, and HL15674 (to W. E. B.).

This article contains supplemental Table S1 and Figs. S1–S8.

1 To whom correspondence should be addressed. E-mail: webalch@scripps.edu.

2 The abbreviations used are: PN, proteostasis network; ER, endoplasmic reticulum; α1ATD, α1-antitrypsin (α1AT) deficiency; HNE, human neutrophil elastase; HDAC, histone deacetylase; HDACi, HDAC inhibitor; SAHA, suberoylanilide hydroxamic acid; CANX, calnexin; siCANX, silencing CANX; Scr, siScramble; CFTR, cystic fibrosis transmembrane conductance regulator; ERAD, endoplasmic reticulum-associated protein degradation.
being the most severe form of the disease (37, 38). The accumulation of Z-variant polymers in the ER can result in proteotoxic stress and associated chronic liver disease (27, 33, 39, 40). In contrast, a defect in ER export of all disease-associated α1AT variants leads to substantially reduced levels in the serum with severe consequences for anti-protease activity in the lung. As such, most α1AT variants found in α1ATD patients trigger lung symptoms with varying times of onset and sensitivity to the environment, particularly smoking, α1AT deficiency being one of the most important risk factor for onset of chronic obstructive pulmonary disease/emphysema (14, 27, 28, 33).

Histone acetyltransferases and deacetylases (HDACs) have recently been shown to play an important role in liver and lung physiology (16, 41–49). Histone acetyltransferase and HDAC mediate, respectively, the post-translational acetylation and deacetylation (50, 51) of histones as well as numerous other luminal and cytosolic proteins, including PN components (22, 52–56) and proteostasis regulatory pathways such as the key heat shock factor 1, involved in regulation of the cytosolic PN (57, 58). Recent studies have suggested that targeting HDAC activity with chemical HDAC inhibitors (HDACi) can provide substantial benefit for type II diabetes (50, 59, 60), cancer (61–63), rheumatoid arthritis (64), and chronic obstructive pulmonary disease/emphysema and asthma-associated airway inflammation (2, 27, 46, 65–67). Additionally, we have previously shown that HDACi can promote trafficking and function of the ΔF508 mutant of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a variant that is responsible for the most common clinical presentation of cystic fibrosis (47, 68). HDACi have also been shown to correct the folding, trafficking, and function of ER-localized mutants of β-glucocerebrosidase, a lysosomal protein that when mutated is responsible for the onset of Gaucher disease, a lysosomal storage disorder (69). The combined studies have led us to propose that HDACi could strongly impact lung biology by altering the acetylation/deacetylation equilibrium (3) to improve trafficking and function (22) of the Z-variant.

Herein we identify an HDACi-sensitive pathway(s) involved in the correction of the defect(s) associated with Z-α1AT trafficking. We demonstrate that the suberoylanilide hydroxamic acid (SAHA)-dependent correction of Z-α1AT secretion operates, at least in part, through HDAC7 by modulating a calnexin-sensitive proteostasis pathway. Further characterization of SAHA-mediated correction of Z-α1AT revealed secretion of a functional Z-α1AT into the medium. The emerging evidence that HDACi can be effectively used to manage multiple misfolding phenotypes in cell and mouse model systems (47, 60, 68, 70–73) leads us to suggest that HDACs are proteostasis regulators (1, 4) that could have an important impact on α1ATD pathobiology and in the management of the misfolding disease in the clinic (22).

**MATERIALS AND METHODS**

**Cell Culture**—Wild-type (WT) and Z-variant IB3 cells (provided by T. Flotte, University of Massachusetts Medical School, Worcester, MA) were cultured in LHC-8 medium containing 10% (v/v) fetal bovine serum (FBS) and 200 μg/ml G418. HCT116 cells were purchased from ATCC (Manassas, VA) and cultured in DMEM containing 10% (v/v) FBS.

**DNA Constructs and Generation of Stable HCT116 Cell Lines**—Human WT and Z-variant (bases 73–1257) of α1AT were PCR-amplified using the following primers: forward (5′-TA CTC GAG GAG CAT CCC CAG GGA GT-3′) and reverse (5′-GTC AGC GGC CGC TTA TTT TTG GGT GGG ATT-3′) and cloned into the Xhol and NotI sites of the pOZ bicistronic retroviral expression plasmid, introducing N-terminal FLAG and HA tags. The α1AT signal peptide (bases 1–72) was cloned upstream of the FLAG tag at the BgIII site of the pOZ vector using annealed oligonucleotides. The HCT116 stable cell lines were generated as described previously (74–76).

**siRNA-mediated Silencing**—IB3 or HCT116 cells were plated in 12-well tissue culture dishes and grown to 40% confluency. Silencing of individual HDACs, EDEM3, ERO1L, and calnexin were performed by transfecting cells with RNAiMax (Invitrogen) and a final concentration of 50 nm siRNA according to the manufacturer’s protocol and as previously described (47).

**α1AT** [35S]Methionine Pulse-labeling—HCT116 cells were incubated for 24 h in the absence or presence of 5 μM SAHA. The cells were washed with 3 changes of PBS and starved for 45 min in methionine-free MEM medium. Starvation medium was replaced with FBS-free growth medium containing 60 μCi of Easy Tag Express [35S]methionine (PerkinElmer Life Sciences), and cells were pulse-labeled for 15 min. The labeling media was subsequently replaced with FBS-free growth media and chased for the indicated times. Cell lysates and media were collected, α1AT was immunoprecipitated, and α1AT was identified by SDS-PAGE as described under “Immunoblotting” below.

**α1AT Secretion Assays**—2 h before measurement of α1AT secretion kinetics, cells were washed with PBS and incubated with 350 μl (12-well plate) or 700 μl (6-well plate) of FBS-free culture medium. After the 2-h incubation, cells were harvested, and the corresponding media were centrifuged at 1500 rpm for 30 min at 4 °C to separate cells and medium. After lysis of the cells, the amount of α1AT in the immature to mature forms in the lysate or secreted into the culture media was analyzed as described under “Immunoblotting” below.

**α1AT-mediated HNE Inhibition Assay**—To determine the activity of secreted α1AT, a fixed amount of media (20 μl) collected in each experiment was incubated with increasing amounts of human neutrophil elastase (0–10 ng) for 30 min at 37 °C. The binding reaction was terminated by the addition of SDS-PAGE buffer, and the samples were subsequently incubated at 95 °C for 5 min. The samples were then resolved by 8% (v/v) SDS-PAGE, transferred to nitrocellulose, and immunoblotted with anti-human α1AT antibody. The densitometry of the SDS-resistant complexes formed between either Z- or WT-α1AT and HNE (5 ng) were quantified using the software ImageJ in the linear region of the exposure.

**Immunoblotting**—Cell lysates were prepared in lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% (v/v) Triton X-100, and protease inhibitors at 2 mg/ml of lysis buffer), and protein concentrations were determined by the Bradford protein assay (Thermo Scientific, Rockford, IL). Total protein and media were resuspended in 1× SDS sample buffer containing β-mercaptoethanol and incubated at 95 °C for 5 min. The samples
10–50 μg of total protein and 10–15 μl of media were then separated on a 10% (v/v) SDS-PAGE, transferred to nitrocellulose, and immunoblotted with anti-human α1AT antibody (Immunology Consultants Laboratory, Newberg, OR) or the indicated antibody. Detection was performed using chemiluminescence and the appropriate horseradish peroxidase-conjugated secondary antibodies. For native gel electrophoresis, 30 μl of cell media were separated on a 3–20% native gel, and an immunoblot analysis of α1AT was performed as described above.

RESULTS

SAHA Corrects Secretion of Z-α1AT—Of the commonly available hepatic and lung cell lines, none endogenously express Z-α1AT but rather exhibit elevated levels of endogenous WT-α1AT, impeding our ability to analyze exogenously expressed Z-α1AT trafficking and secretion. To overcome this limitation, we generated cell culture models to study the contribution of proteostasis management on Z-α1AT trafficking. These include a human epithelial colorectal carcinoma cell line (HCT116) expressing N-terminal FLAG-tagged WT- or Z-α1AT, referred to as WT- and Z-HCT116, and a human bronchial epithelial cell line (IB3) expressing non-tagged WT- or Z-α1AT, referred to as WT- and Z-IB3. Traffic of the α1AT glycoprotein through the secretory pathway can be monitored by a change in its migration on SDS-PAGE in response to the processing of ER-acquired by a change in its migration on SDS-PAGE in response to the glycoprotein through the secretory pathway can be monitored for native cell gel electrophoresis, 30 μl of cell media were separated on a 3–20% native gel according to the manufacturer's instructions (Expedeon Inc., San Diego, CA), and immunoblotting was performed as described above for SDS-PAGE. Hsp90 was used in general as loading control.

Analysis of Human Plasma Samples—Plasma samples from Z/Z (Z-α1AT) and M/M (WT-α1AT) individuals were separated on a 3–20% gradient native gel, and an immunoblot analysis of α1AT was performed as described above.

HDACi-Proteostasis Regulation of α1-Antitrypsin Deficiency

NOVEMBER 2, 2012 • VOLUME 287 • NUMBER 45

SAHA and Scriptaid exhibiting the highest level of benefit in restoring the secretion of Z-α1AT into the culture medium (Fig. 1A). Identical results were observed for SAHA and Scriptaid treatments in the Z-IB3 cell line expressing non-tagged α1AT (supplemental Fig. S1C), thereby indicating that the N-terminal FLAG tag used in HCT116 had no effect on the observed SAHA and Scriptaid-mediated correction. Because SAHA promoted efficient trafficking and is also an Food and Drug Administration-approved drug for management of metastatic disease, we focused our study on this compound.

To better characterize the SAHA-mediated correction of Z-α1AT, both Z-HCT116 and Z-IB3 cells were treated with increasing concentrations of SAHA for 24 h (Fig. 1B and supplemental Fig. S1C). SAHA improved Z-α1AT trafficking and secretion in a dose-dependent manner, and correction was observed at concentrations as low as 0.5 μM, with maximal response observed at 5 μM (Fig. 1B and supplemental Fig. S1C). We also observed a dose-dependent increase in Z-α1AT mRNA starting at 0.5 μM (supplemental Fig. S1D), suggesting that the SAHA-mediated correction could, at least in part, be due to an increase in Z-α1AT transcription. WT-α1AT was equally responsive to SAHA, exhibiting an increased secretion at the 5 μM dosing (supplemental Fig. S1, E–F). Because both the WT and Z-variant exhibited increased trafficking and secretion in response SAHA treatment suggests that the SAHA-mediated correction of the Z-variant trafficking occurs via a conserved on-pathway mechanism.

To analyze the kinetics of the SAHA-mediated rescue of Z-α1AT in HCT116 cells, we performed a time course analysis using the optimal 5 μM dosing (Fig. 1C). We observed an increased level of the ER-localized immature (I) Z-α1AT after 8 h of treatment (Fig. 1C and supplemental Fig. S1G) and the appearance of both the mature (M) glycoform and secreted (S) Z-α1AT after 12 h of treatment (Fig. 1C and supplemental Fig. S1G). An apparent 1.5- and 1.8-fold increase in α1AT mRNA was seen at 8 and 12 h, respectively, as compared with DMSO (supplemental Fig. S1H). The difference in mRNA levels between these two time points was not statistically significant. However, an examination of the Z-α1AT protein levels in this same 4-h window revealed some important differences including 1) a statistically significant (~50%) increase in the level of the ER-associated immature glycoform, 2) restoration of intracellular trafficking of Z-α1AT as evidenced by the appearance of the steady-state level of mature Golgi processed glycoform, and 3) a 7-fold increase in the secretion of the Z-variant relative to the basal level seen upon DMSO treatment (Fig. 1C and supplemental Fig. S1G). A significant increase in histone H3 acetylation was also observed as early as 2 h post-dosing with drug, consistent with the known epigenetic changes induced by SAHA (Fig. 1C). In contrast, no change in α1AT mRNA could be detected until 8 h post-treatment. These results suggest that, in addition to the apparent slight increase in expression or stability of Z-α1AT mRNA in response to SAHA, additional components could be transcriptionally and/or post-translationally impacted by SAHA through an HDAC-mediated mechanism(s), thereby contributing to the increased trafficking and secretion of Z-α1AT.
Given the elevated expression of the intracellular pool of Z-α1AT seen in response to SAHA treatment (Fig. 1A), we wanted to determine if the observed correction reflected a proportional “leak” of the misfolded ER pool into the secretory pathway or if we had achieved an increase in trafficking efficiency. An analysis of Z-α1AT trafficking when overexpressed at a level similar to that seen after SAHA treatment (supplemental Fig. S2A) revealed a level of maturation and secretion that was substantially lower than that observed in the presence of SAHA (supplemental Fig. S2A). To further characterize the differences in secretion between Z-α1AT overexpression and SAHA treatment, we analyzed the fractional distribution of Z-α1AT between the immature, mature, and secreted pools. Despite achieving a similar level of total Z-α1AT expression with both conditions (supplemental Fig. S2A), we observed that the mature and secreted pools of Z-α1AT were significantly
higher in response to SAHA treatment, which was accompa-
nied by a concomitant decrease in the immature glycoform (supplemental Fig. S2B). Conversely, the overexpression of Z-α1AT did not alter the fractional distribution of the various glycoforms as compared with that seen in the control condi-
tions. These results indicate that the SAHA-mediated correc-
tion of Z-α1AT does not occur as a result of a proportional leak in response to Z-α1AT overexpression but rather from an alter-
tation in the efficiency of Z-α1AT synthesis, folding, and/or traf-
ficking, leading to productive maturation and secretion from the cell.

To confirm the above results, we performed a pulse-chase analysis using optimized SAHA dosing conditions (5 μM for 24 h) in Z-HCT116 cells (Fig. 1D). We observed that SAHA treatment caused an initial delay in the decay of the ER pool of Z-α1AT (Fig. 1E), supporting our hypothesis that this HDACi mediates an increased stability of the Z-variant. This initial increased stability was followed by a linear decay of the immat-
ture glycoform that was more rapid than that seen with vehicle

SAHA Partially Corrects Z-α1AT Trafficking Defect through HDAC7—The dose-dependent correction of Z-α1AT by SAHA in Z-HCT116 cells correlated with reduced levels of HDAC7 (Fig. 1B), a result consistent with previous reports on the effect of SAHA on HDAC7 expression (47, 80). To address the role of HDAC7 and possibly other HDACs (81) in the SAHA-mediated correction of Z-α1AT trafficking defect, we examined the effect of siRNA-mediated HDAC silencing in both the Z-HCT116 and Z-IB3 cell models. Upon examining the 11 members that make up the class I, II, and IV HDACs, only the silencing of HDAC7 (supplemental Fig. S3, A and B) resulted in correction of Z-α1AT in both Z-HCT116 (Fig. 3A) and Z-IB3 cells (Fig. 3B), yielding a 3- and 6-fold increase in Z-variant secretion, respectively (Fig. 3, A and B). The silencing of HDAC7 resulted in an ∼2.5-fold increase in α1AT mRNA expression (supplemental Fig. S3C) similar to the ∼3-fold increase observed after SAHA treatment (supplemental Fig. S3C).

To provide additional support for our interpretation that the observed SAHA-mediated correction of Z-α1AT can act through HDAC7, we compared the effect of SAHA treatment alone or in combination with HDAC7 silencing (supplemental Fig. S4). Both siHDAC7 and SAHA treatments increased the stability of the immature pool of the Z-variant and restored maturation and secretion of Z-α1AT (supplemental Fig. S4). Combining the SAHA and siHDAC7 treatments did not further increase the stability of the ER-localized immature glycoform of the Z-α1AT compared with that seen with SAHA treatment alone (supplemental Fig. S4), raising the possibility that the increased stability of the Z-variant in the ER seen in response to SAHA acts through HDAC7. The combined treatment did
result in an increase in maturation and secretion of Z-α1AT compared with either treatment alone (supplemental Fig. S4), but these effects were less then additive, suggesting that the SAHA-mediated trafficking correction also acts, at least in part, through an HDAC7-dependent mechanism. An analysis of the level of HDAC7 silencing seen in response to SAHA treatment alone or in combination with siHDAC7 treatment revealed a significant difference in the extent of HDAC7 knockdown (supplemental Fig. S4, upper) under these two conditions with the combined having a greater silencing (supplemental Fig. S4, upper). This differential HDAC7 silencing could explain the variable correction of Z-α1AT secretion seen with SAHA treatment alone or in combination with siHDAC7 treatment, with the latter having a more pronounced corrective benefit as well as an increased HDAC7 knockdown.

SAHA/siHDAC7-mediated Correction of Z-α1AT Acts through the Calnexin Glycoprotein Cycle—A number of signaling pathways are activated by protein misfolding in the ER, including the unfolded protein response, which can be monitored by the phosphorylation state of eIF2α, the ER-overload response, which can be monitored by the phosphorylation state and degradation of IκB (p-IκB), and autophagy, which can be monitored by the amount of cleavage of LC3. Neither SAHA nor siHDAC7 treatments activated these pathways.
HDACi-Proteostasis Regulation of α1-Antitrypsin Deficiency

(folding in the ER (11), and it has recently been suggested to affect the trafficking of α1AT (82) as well as many other proteins including, for example, ΔF508-CFTR, the latter variant of which is corrected by both SAHA and siHDAC7 (47). Although we did not detect any change in the expression levels of calnexin in response to SAHA (supplemental Fig. S5B), we did detect a statistically significant 2- and 1.2-fold reduction in the recovery of calnexin with Z-α1AT by co-immunoprecipitation, in response to SAHA or siHDAC7 treatment, respectively (Fig. 4A and supplemental Fig. S5C). This decreased level of interaction was not due to a saturation of the available calnexin pool due to increased expression of Z-α1AT, as a significant (>99%) amount of the total calnexin remained in the unbound material, whereas 99% of the Z-α1AT was recovered in the immunoprecipitate (supplemental Fig. S5D). Given that SAHA and siHDAC7 are able to restore the trafficking of ΔF508-CFTR (47, 87) (supplemental Fig. S6, A and B), we monitored the binding of calnexin to ΔF508-CFTR. As for Z-α1AT, we also observed a decreased recovery of calnexin in response to both SAHA and siHDAC7 treatments (supplemental Fig. S6, A and B).

To further address the role of calnexin in the SAHA-mediated correction of Z-α1AT, we examined the effect of two drugs known to alter the affinity of nascent proteins for calnexin: 1) miglustat, an inhibitor of glucosidases I and II, both of which are necessary for the proper cycling of calnexin from the nascent polypeptide chain during folding (88), and 2) kifunensine, an inhibitor of the ER α-1,2-mannosidase, whose activity is required to allow improperly folded proteins to exit the calnexin cycle and enter the degradation pathway (89, 90). As previously demonstrated (91–93), kifunensine treatment resulted in a modest increase in Z-α1AT secretion, whereas miglustat had no significant effect (Fig. 4B). When the SAHA and kifunensine treatments were combined, a decrease in Z-α1AT secretion was observed relative to that seen with SAHA alone, whereas miglustat again had no effect (Fig. 4B). Because the action of α-1,2-mannosidase is critical for the exit of client proteins from the calnexin cycle (82, 90), these results suggest that the SAHA-mediated correction proceeds through a similar pathway. These results are also consistent with the observation that SAHA-mediated disruption of the calnexin-α1AT interaction is inhibited in the presence of kifunensine but not in the presence of miglustat (Fig. 4C and supplemental Fig. S6C). Therefore, we raise the possibility that the calnexin/α1AT interaction represents a mechanistic target for the SAHA-mediated correction of Z-α1AT trafficking. For example, one possibility is that SAHA generates a more favorable ER folding environment that allows the Z-α1AT to acquire a stable fold and hence avoid the glycoprotein ERAD (GERAD) (93).

To provide further support for our interpretation that reducing the interaction of Z-α1AT with calnexin can restore the trafficking and secretion of the Z-variant, we tested the effect of silencing calnexin (siCANX) on Z-α1AT biogenesis. After calnexin silencing, we observed a 3-fold increase in the level of the immature form (Fig. 5, A and B), a 2-fold increase in the mature form (Fig. 5, A and C), and a 3-fold increase in the secreted pool (Fig. 5, A and D) of Z-α1AT relative to the siScramble (Scr)-transfected control. The level of correction seen upon calnexin silencing was similar to that seen with SAHA treatment alone.

Given that α1AT is a luminal glycoprotein, we focused our attention on PN pathways unique to the ER that manages glycoprotein folding. We first investigated the relationship between Z-α1AT folding and the calnexin cycle in response to SAHA because calnexin is a major regulator of glycoprotein

**FIGURE 3. Silencing of HDAC7 corrects Z-α1AT maturation and secretion.** Immunoblot analysis of Z-α1AT protein expression in cell lysates (upper panels; I, immature; M, mature) and culture media (middle panels; S, secreted) after siRNA-mediated silencing of HDACs 1–11 in Z-HCT116 cells (A) and Z-IB3 cells (B). Quantitative analysis of the level of secreted Z-α1AT in response to silencing of the indicated HDAC in Z-HCT116 (A) and Z-IB3 (B) cells. Data shown denote the -fold change in secreted Z-α1AT relative to scramble (Scr) control (mean ± S.D., n = 3). In all panels asterisks indicate p < 0.05 as determined by two-tailed t test using Scr control as the reference. (supplemental Fig. S5A) nor did they alter the protein expression levels of calnexin, ERGIC53, protein disulfide isomerase, the ER-associated binding immunoglobulin protein (BiP), and valosin-containing protein (VCP/p97), known α1AT interacting partners thought to facilitate its folding, trafficking, and degradation (35, 82–87) (supplemental Fig. S5B).
HDACi-Proteostasis Regulation of α1-Antitrypsin Deficiency

FIGURE 4. SAHA treatment alters calnexin binding to Z-α1AT. A, immunoblot and quantitative analyses of Z-α1AT and calnexin (CANX) from an immunoprecipitation (IP) of Z-α1AT from Z-HCT116 cells treated with DMSO or 5 μM SAHA for 24 h are shown. B, immunoblot and quantitative analyses of the level of secreted Z-α1AT after treatment of Z-HCT116 cells with 100 μM miglustat (MIG), 2 μg/ml kifunensine (KIF), or vehicle (Veh) for 24 h in the presence (white bars) or absence (black bars) of 5 μM SAHA. The data represent the fold change relative to vehicle control (mean ± S.D., n = 3). C, immunoblot and quantitative analyses of Z-α1AT and CANX from an immunoprecipitation of α1AT from Z-HCT116 cells treated with vehicle (Veh), 2 μg/ml kifunensine, or kifunensine + 5 μM SAHA for 24 h. The data in A and C are shown as a ratio of recovered calnexin to immature (I) Z-α1AT (mean ± S.D., n = 3) relative to DMSO. In all panels, # and * indicate p < 0.05 as determined by two-tailed t test using SAHA + vehicle (#) or vehicle (*) as the reference.

(Fig. 5, A–D). When SAHA treatment was combined with calnexin silencing, we observed an additive effect (Fig. 5, A–D), suggesting that disruption of the calnexin-client interaction is not solely responsible for the observed effect of SAHA in correcting the defect associated with the Z-α1AT.

Modification of the ER Proteostasis Environment upon SAHA Treatment—Given the above observations, we next attempted to identify additional components of the ER PN that could affect the trafficking of Z-α1AT. To identify changes in the ER PN, we investigated the effect of SAHA on the expression of 84 genes involved in ER-associated folding, degradation, post-translational modification, and signaling (supplemental Table S1). We observed that 7 genes exhibited a reduced expression, and 9 genes showed an increased expression (>2-fold) in response to SAHA treatment (Fig. 6A). An analysis of the functional relationship between these genes revealed that α1AT is tightly linked to the glycoprotein ERAD machinery through EDEM3, OS9, and SEL1L, whose expressions were increased upon SAHA treatment. This pathway has already been reported to be involved in the degradation of misfolded, ER-localized glycoprotein including another α1AT mutant, the Null Hong-Kong (NHK) species (94, 95). Thus, it is reasonable to conclude that EDEM3-OS9-SEL1L would also contribute to the degradation of the Z-variant. The results above reveal that although SAHA mediates an increased expression of Z-α1AT itself, it is also offset with an increased expression of the glycoprotein ERAD pathway charged with its degradation should it fail to fold properly. This suggests that the observed correction in response to SAHA is not a result of simply overwhelming the ER retention pathways typically associated with the Z-variant. Moreover, when EDEM3-silenced cells were treated with SAHA, we observed a synergistic effect on Z-α1AT correction (supplemental Fig. S7A), suggesting that SAHA and siEDEM3 target the Z-variant correction via parallel pathways. These results once again support a model of the SAHA-mediated correction of Z-α1AT without interfering or saturating the degradation pathway of the Z-variant.

To confirm a potential role for SAHA as a more general proteostasis regulator of α1AT biology, we further analyzed the contribution of ERO1L in the biogenesis of α1AT. We first analyzed the effect of SAHA on ERO1L expression levels (supplemental Fig. S7B). Both ERO1L mRNA and protein expression were reduced after SAHA treatment (Fig. 6A and supplemental Fig. S7B). To address whether the reduced ERO1L levels contribute to the observed SAHA-mediated rescue of Z-α1AT, we next monitored the trafficking ability of the Z-variant after siRNA-mediated silencing of ERO1L (siERO1L). The silencing of ERO1L caused an increase in the level of immature (1.8-fold), mature (2.3-fold), and secreted (1.8-fold) Z-α1AT relative to that seen in scramble control (Fig. 6B), which was further increased upon the addition of SAHA (Fig. 6B). This result indicates that SAHA acts, at least in part, through silencing of ERO1L and provides evidence that it represents a general proteostasis regulator capable of targeting key pathways mediating...
HNE-mediated degradation of even WT-mental Fig. S8

WT-incubated with a fixed amount of media recovered from SDS-PAGE (91, 96). Briefly, increasing quantities of HNE were

The HNE complex. As expected, the WT-

Supershift to a higher molecular weight species representing the HNE complex. As expected, the WT-

the biogenesis of Z-α1AT and correction of its trafficking defect.

SAHA Restores Z-α1AT Anti-protease Activity—Because we observed correction of Z-α1AT secretion in response to SAHA treatment, we tested whether the secreted Z-variant had anti-protease activity. To monitor this activity, we exploited the ability of α1AT to form an SDS-resistant complex with HNE, leading to a slower migration of the α1AT-HNE complex on SDS-PAGE (91, 96). Briefly, increasing quantities of HNE were incubated with a fixed amount of media recovered from WT-α1AT- or Z-α1AT-secreting cells. The resulting complexes were analyzed by SDS-PAGE for evidence of α1AT supershift to a higher molecular weight species representing the HNE complex. As expected, the WT-α1AT secreted by WT-HCT116 cells formed a higher molecular weight complex with HNE (Fig. 7A, top panel). Because SDS-resistant complexes were not observed when conditioned media from parental HCT116 cells was used, these complexes arise from the secretion of WT-α1AT (supplemental Fig. S8A). In contrast to the WT-α1AT result, no supershift was detected when the media from DMSO-treated Z-HCT116 cells were used (Fig. 7A, middle panel) or, surprisingly, siHDAC7-treated cells (supplemental Fig. S8B). However, given the sensitivity of the assay to HNE-mediated degradation of even WT-α1AT (Fig. 7A, top panel), we cannot rule out the possibility that the low level of secretion of the endogenous pool of Z-α1AT (DMSO vehicle) or that observed in the presence of siHDAC7 was degraded, precluding detection of the complexes. In contrast, in SAHA-treated cells the secreted Z-α1AT showed significant incorporation into SDS-resistant complexes when compared with that observed with the WT-α1AT (Fig. 7A, bottom panel). To identify the fraction of this SAHA-stimulated pool of Z-α1AT that retained SERPIN activity, we quantified the SDS-resistant complexes formed between Z- or WT-α1AT in the presence of similar levels of α1AT in the media and 5 ng HNE (Fig. 7B). We detected a 50% recovery of SDS-resistant Z-variant complexes relative to that seen with WT-α1AT (Fig. 7B), indicating that whereas the SAHA-mediated secreted pool does not restore the full level of activity seen with WT-α1AT, it retains sufficient activity to give a robust response in the HNE binding assay. This difference could be explained by the fact that Z-α1AT is secreted largely as a polymeric pool after SAHA treatment (Fig. 7C), consistent with the polymeric state found in plasma of Z-variant patients (Fig. 7D).

DISCUSSION

Herein, we report the improved secretion of an active species of Z-α1AT in response to SAHA. The mechanism of action for this HDACi-mediated correction is sensitive in part to the reduction of the levels of HDAC7 and to the modulation of the interaction of Z-α1AT with the ER glycoprotein chaperone calnexin that is likely linked to the activity of other ER PN components including ERO1L and the EDEM3-OS9-SEL1L complex.

Our results are in agreement with the increasing evidence that the cellular acetylome balance, managed through the opposing activities of histone acetyltransferases and HDACs, plays an important role as a key regulator of protein folding. Indeed, there is increasing evidence that HDAC pathways play a critical role in managing multiple protein structure relationships. HDACs are particularly well characterized for their impact on the quaternary structure of histones, controlling the dynamics of nucleosome assembly, leading to their ability to control access of DNA to the activity of transcription factors. Moreover, it is also now appreciated that HDACs have a strong influence on the activity of Hsp90 and the activity of heat shock factor 1 (6, 13, 57), the key transcription factor controlling the heat shock response favoring increased protection to protein misfolding. We have suggested that both histone and non-histone post-translational acetylation events represent only small part of the total cellular acetylome now recognizes to be managed by the acetylation proteostasis system (22, 97, 98).

Our characterization of the mechanism of action for the HDACi-mediated correction indicates that SAHA, at least in part, modulates the interaction between the N-glycans of Z-α1AT and the calnexin folding machinery. The latter is a key ER proteostasis component that recognizes glycoprotein-folding intermediates including α1AT and manages their folding (35, 82, 99–101). Thus, our data are consistent with the idea that SAHA targets a very early folding intermediate. Several different mechanisms could account for the ability of SAHA to alter the calnexin/client interaction and/or its interaction with additional ER PN components including degradative and/or redox-coupled components associated with folding steps. Calnexin is reported to be acetylated at Lys-137, a post-translation modification that localizes to the lectin domain of the protein.
Therefore, a possible model whereby the acetylation state of calnexin alters the conformation of the lectin motif and inhibits its ability to associate with the maturing glycan chain of client proteins remains possible. This hypothesis is supported by the recent discovery of a class I HDAC(s) in the lumen of the ER (102), although a mechanism of their putative translocation into the ER lumen remains to be explained. Alternatively, and/or in addition, the trafficking of the Z-variant protein could be corrected in response to SAHA treatment through known proteostasis events discussed above and/or unknown HDACi-sensitive pathways. The latter could involve ER and/or cytosolic acetylation proteostasis system-sensitive trafficking components that must be aligned early in the folding process for effective ER export (7, 22, 47, 68). In agreement with this view, our preliminary systems level assessment of SAHA-mediated changes in gene expression of ER-associated PN components revealed altered expression of multiple proteins known to be functionally coupled to calnexin and that could contribute to the overall folding environment of the ER promoting WT folding and trafficking. Moreover, a model involving histone modification and correction through epigenetic pathways that affect trafficking is consistent with the persistence of the corrective effect of a low dose, chronic SAHA treatment regimen after compound withdrawal.

The role of SAHA as a regulator of PN biology affecting α1AT export is similar to our recent proposal for SAHA-mediated correction of ΔF508-CFTR (47), where alterations in the PN pathways contribute to the restoration of mutant function. Moreover, the need to energetically stabilize Z-α1AT for export through the PN is consistent with the recent use of the tetrapeptide chemical chaperone, TTAI, that binds the loop-sheet cleft defective in disease and that
significantly improves the export of an HNE reactive Z-α1AT to the medium (103).

Our combined results lead us to suggest a model for the correction of Z-variant disease that reflects the role of multiple α1AT folding intermediates in the ER (Fig. 8) that contribute to degradative, polymer prone, and/or export pathways impacted by treatment with SAHA. In non-treated conditions (Fig. 8, left) Z-α1AT could in principle be found in up to four different biosynthetic pools, likely reflecting steps normally transiently occupied by WT α1AT. These include: 1) the pool being actively managed through the calnexin cycle (orange circles); 2) the major (>85%) pool targeted for degradation by the ERAD pathway (including its links to EDEM3-OS9-SEL1L) after hand-off from calnexin (blue circles); 3) a minor but cumulative toxic aggregated pool triggering liver disease (clustered black circles) (14, 29, 104–106); 4), an inefficiently secreted but partially active polymeric Z-α1AT pool that can be found in serum of Z-variant patients (clustered orange circles in Golgi and extracellular pools) (107). After SAHA treatment (right), we suggest that Z-α1AT is redistributed between the various pools to promote export. We observe a decrease in the ER retained Z-α1AT accompanied by an increase in the ERAD pathway as well as increased secretion of a functional form Z-α1AT (green circles). We suggest that the HDAC SAHA promotes remodeling of the ER proteostasis network either transcriptionally and/or post-translationally (PTM) to partially restore the secretion of functional Z-α1AT.

Curiously, targeting the pathway(s) that alters the cell capacity to correct trafficking defect of Z-α1AT by SAHA did not alleviate the aggregate pool nor activate autophagy pathways and thus may not reduce liver pathophysiology as occurs with carbamazepine (105). Rather, we would suggest that SAHA would have its main effect on the protection and/or restoration of lung function through the increased generation of a soluble secreted, functional pool (14, 105, 110). However, because HDACi have recently been reported to induce autophagy (111), the potential impact of select HDACi on aggregate load in the hepatocyte disease will require further investigation. Moreover, the impact of correction by SAHA on the propensity of Z-α1AT to generate a more monomeric versus the polymeric species that can be detected in serum of patients remains to be further explored (107) (Fig. 8, orange versus green circles (37)). Interestingly, combining EDEM3 silencing, which attenuates the glycoprotein ERAD pathway, with SAHA treatment, which modulates the calnexin-α1AT interaction favoring export, had a synergistic effect on the secretion of Z-α1AT. This observation suggests that the joint modulation of these pathways, both of
HDACi-Proteostasis Regulation of α1-Antitrypsin Deficiency

which may limit the effective recovery of the Z-variant for export from ER, will provide a more significant therapeutic benefit for α1ATD than either alone.

In summary, our results show that SAHA and potentially other Zn^{2+}-dependent class I, II, and/or IV pan HDACi can manage the activity of key pathways that influence the export of Z-variant α1AT in a fashion that can restore biological extra-cellular function (Fig. 8). Because SAHA and HDACi also overcome other disease-causing mutations including the correction of the trafficking and function of the ΔF508 CFTR variant responsible for cystic fibrosis (47), we propose that histone acetyltransferases/HDACs may function as more general proteostasis regulators (1).

Acknowledgments—We thank the α-1 Foundation and Dr. M. Brantly for generous help in the acquisition of Z-α1AT variant patient serum.

REFERENCES

1. Balch, W. E., Morimoto, R. I., Dillin, A., and Kelly, J. W. (2008) Adapting proteostasis for disease intervention. Science 319, 916–919
2. Boucheclaireil, M., and Balch, W. E. (2011) Proteostasis. A new therapeutic paradigm for pulmonary disease. Proc. Am. Thorac. Soc. 8, 189–195
3. Hutt, D., and Balch, W. E. (2010) Cell Biology. The proteome in balance. Science 329, 766–767
4. Powers, E. T., Morimoto, R. I., Dillin, A., Kelly, J. W., and Balch, W. E. (2009) Biological and chemical approaches to diseases of proteostasis deficiency. Annu. Rev. Biochem. 78, 959–991
5. Ont, D. S., and Kelly, I. W. (2011) Chemical and/or biological therapeutic strategies to ameliorate protein misfolding diseases. Curr. Opin. Cell Biol. 23, 231–238
6. Gidalevitz, T., Prahlad, V., and Morimoto, R. I. (2011) The stress of protein misfolding. From single cells to multicellular organisms. Cold Spring Harb. Perspect. Biol. 3, a009704
7. Balch, W. E., Roth, D. M., and Hutt, D. M. (2011) Emergent properties of proteostasis in managing cystic fibrosis. Cold Spring Harb. Perspect. Biol. 3, a004999
8. Roth, D. M., and Balch, W. E. (2011) Modeling general proteostasis. Proteome balance in health and disease. Curr. Opin. Cell Biol. 23, 126–134
9. Taylor, R. C., and Dillin, A. (2011) Aging as an event of proteostasis collapse. Cold Spring Harb. Perspect. Biol. 3, a004440
10. Määtänen, P., Gehring, K., Bergeron, J. J., and Thomas, D. Y. (2010) Heat shock factors. Integrators of cell stress, development, and lifespan. Nat. Rev. Mol. Cell Biol. 11, 545–555
11. Perlmutter, D. H. (2011) α1-Antitrypsin deficiency. Importance of proteasomal and autophagic degradative pathways in disposal of liver disease-associated protein aggregates. Annu. Rev. Med. 62, 333–345
12. Kroemer, G., Marinho, G., and Levine, B. (2010) Autophagy and the integrated stress response. Mol. Cell 40, 280–293
13. Shakespear, M. R., Halili, M. A., Irvine, K. M., Fairlie, D. P., and Sweet, M. J. (2011) Histone deacetylases as regulators of inflammation and immunity. Trends Immunol. 32, 335–343
14. Malhi, H., and Kaufman, R. J. (2011) Endoplasmic reticulum stress in liver disease. J. Hepatol. 54, 795–809
15. Kitamura, M. (2011) Control of NF-κB and inflammation by the unfolded protein response. Int. Rev. Immunol. 30, 4–15
16. Grabiec, A. M., Tak, P. P., and Reedquist, K. A. (2011) Function of histone deacetylase inhibitors in inflammation. Crit. Rev. Immunol. 31, 233–263
17. Belorgey, D., Irving, J. A., Ekeowa, U. I., Freeke, J., Roussel, B. D., Miranda, E., Pérez, J., Robinson, C. V., Marcinia, S. J., Crowther, D. C., Michel, C. H., and Lomas, D. A. (2011) Characterization of serum polymers in vitro and in vivo. Methods 53, 255–266
18. Singh, S., Vishni, S., Singh, B. K., Rahman, I., and Kakkar, P. (2010) Nrf2-ARE stress response mechanism. A control point in oxidative stress-mediated dysfunctions and chronic inflammatory diseases. Free Radic. Res. 44, 1267–1288
19. Hutt, D. M., and Balch, W. E. (2012) Cold Spring Harb. Perspect. Biol., in press
20. Oliveberg, M., and Wolynes, P. G. (2005) The experimental survey of protein-folding energy landscapes. Q. Rev. Biophys. 38, 245–288
21. Eichner, T., and Radford, S. E. (2011) A diversity of assembly mechanisms of a generic amyloid fold. Mol. Cell 43, 8–18
22. Lindquist, S. L., and Kelly, J. W. (2011) Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases. Progress and prognosis. Cold Spring Harb. Perspect. Biol. 3, a004507
23. Kikis, E. A., Gidalevitz, T., and Morimoto, R. I. (2010) Protein homeostasis in models of aging and age-related conformational disease. Adv. Exp. Med. Biol. 694, 138–159
24. Ekeowa, U. I., Marciniak, S. J., and Lomas, D. A. (2011) Hepatic fibrosis and carcinogenesis in α1-antitrypsin deficiency. A prototype for chronic tissue damage in gain-of-function disorders. Cold Spring Harb. Perspect. Biol. 3, a005801
25. Flotte, T. R., and Mueller, C. (2011) Gene therapy for α1-antitrypsin deficiency. Hum. Mol. Genet. 20, R87–R92
26. Gooptu, B., Ekeowa, U. I., and Lomas, D. A. (2009) Mechanisms of emphysema in α1-antitrypsin deficiency. Molecular and cellular insights. Eur. Respir. J. 34, 475–488
27. Ekeowa, U. I., Freeke, J., Miranda, E., Gooptu, B., Bush, M. F., Pérez, J., Teckman, J., Robinson, C. V., and Lomas, D. A. (2010) Defining the mechanism of polymerization in the serpinopathies. Proc. Natl. Acad. Sci. U.S.A. 107, 17146–17151
28. Sifers, R. N. (2010) Medicine. Clearing conformational disease. Science 329, 154–155
29. To, M., Yamamura, S., Akashi, K., Charron, C. E., Barnes, P. J., and Ito, K. (2011) Molecular basis of α1-antitrypsin deficiency and inflammation. Expert Rev. Clin. Immunol. 7, 243–252
30. Gooptu, B., and Lomas, D. A. (2009) Conformational pathology of the serpins. Themes, variations, and therapeutic strategies. Annu. Rev. Biochem. 78, 147–176
31. Yamasaki, M., Sendall, T. J., Pearce, M. C., Whiston, J. C., and Hunting, J. A. (2011) Molecular basis of α1-antitrypsin deficiency revealed by the structure of a domain-swapped trimer. EMBO Rep. 12, 1001–1017
32. Stoller, J. K., and Aboussouan, L. S. (2012) A review of α1-antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 185, 246–259
33. Kelly, E., Greene, C. M., Carroll, T. P., McElvaney, N. G., and O’Neill, S. J. (2010) α1-antitrypsin deficiency. Respir. Med. 104, 763–772
34. Topic, A., Proik, D., and Stankovic, I. (2011) α1-Antitrypsin deficiency in early childhood. Fetal Pediatr. Pathol. 30, 312–319
35. Marcinia, S. J., and Lomas, D. A. (2010) α1-Antitrypsin deficiency and autophagy. N. Engl. J. Med. 363, 1863–1864
36. To, M., Yamamura, S., Akashi, K., Charron, C. E., Barnes, P. J., and Ito, K. (2012) Defect of adaptation to hypoxia in patients with COPD due to reduction of histone deacetylase 7. Chest 141, 1233–1242
37. Mizuno, S., Yasuo, M., Bogaard, H. J., Krakauskas, D., Narashen, R., and Voelkel, N. F. (2011) Inhibition of histone deacetylase causes emphysema. Am. J. Physiol. Lung Cell Mol. Physiol. 300, L402–L413
38. Min, T., Bodas, M., Mazur, S., and Vuj, N. (2011) Critical role of proteostasis. Imbalance in pathogenesis of COPD and severe emphysema. J. Mol. Med. 89, 577–593
44. Mercado, N., Thimmulappa, R., Thomas, C. M., Fenwick, P. S., Chana, K. K., Donnelly, L. E., Biswal, S., Ito, K., and Barnes, P. J. (2011) Decreased histone deacetylase 2 impairs Nr2f2 activation by oxidative stress. Biochem. Biophys. Res. Commun. 406, 292–298

45. Isajevs, S., Trivedi, C. M., Damara, G., Jiang, M., Damera, G., Jiang, M., Jester, W., Hoshi, T., Epstein, J. A., and Panettieri, R. A., Jr. (2012) Trichostatin A abrogates airway constriction, but not inflammation, in murine and human asthma models. Am. J. Respir. Cell Mol. Biol. 46, 132–138

46. Hutt, D. M., Herman, D., Rodrigues, A. P., Noel, S., Pilewski, J. M., Mattheson, J., Hoch, B., Kellner, W., Kelly, J. W., Schmidt, A., Thomas, P. I., Matsumura, Y., Skach, W. R., Gentsch, M., Riordan, J. R., Sorscher, E. J., Okiyonoeda, T., Yates, J. R., Srd, Lukacs, G. L., Frizzell, R. A., Manning, G., Gottesfeld, J. M., and Balch, W. E. (2010) Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat. Chem. Biol. 6, 25–33

47. Chung, K. F., and Marwick, J. A. (2010) Molecular mechanisms of oxidative stress in airways and lungs with reference to asthma and chronic obstructive pulmonary disease. Ann. N. Y. Acad. Sci. 1203, 85–91

48. Rajendraasahan, S., Yao, H., and Rahman, I. (2009) Current perspectives on role of chromatin modifications and deacetylases in lung inflammation in COPD. COPD 6, 291–297

49. Peserico, A., and Simone, C. (2011) Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J Biomed. Biotechnol. 2011, 371832

50. Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Beebe, K., Cotter, R. J., Felts, S., Toft, D., Karnitz, L., Rosen, N., and Neumann, A. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834–840

51. Mollapour, M., and Neckers, L. (2012) Post-translational modifications of Hsp90 and their contributions to chaperone regulation. Biochim. Biophys. Acta 1823, 648–655

52. Cook, C., and Petrucci, L. (2012) Tau triage decisions mediated by the chaperone network. J Alzheimers Dis., in press

53. Keckapure, V. D., Dammenberg, A. I., and Subbaraoaiah, K. (2009) HDAC6s modulate Hsp90 chaperone activity and regulate activation of aryl hydrocarbon receptor signaling. J. Biol. Chem. 284, 7436–7445

54. Scroggins, B. T., Robisky, K., Wang, D., Marcu, M. G., Tsutsui, S., Beeke, K., Cotter, R. J., Felts, S., Toft, D., Karnitz, L., Rosen, N., and Neckers, L. (2007) An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol. Cell 25, 151–159

55. Murphy, P. J., Morishima, Y., Kovacs, J. J., Yao, T. P., and Pratt, W. B. (2005) Regulation of the dynamics of hsp90 action on the glucocorticoid receptor, Sirtuin 1, and age-related diseases. J Biol. Chem. 280, 33792–33799

56. Zeng, L., Chen, R., Liang, F., Tsuchiya, H., Murai, H., Nakahashi, T., Iwai, R., O., Görgün, C. Z., and Hotamisligil, G. S. (2006) Chemical chaperones with and without chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 362–371

57. Buckland, J., Yao, H., and Rahman, I. (2009) Combined proteasome and histone deacetylase inhibition. A promising synergy for patients with relapsed/refractory multiple myeloma. Leuk. Res. 34, 1111–1118

58. Marwick, J. A., Ito, K., Adcock, I. M., and Kirkham, P. A. (2007) Oxidative stress and steroid resistance in asthma and COPD. pharmacological manipulation of HDAC-2 as a therapeutic strategy. Exp. Opin. Ther. Targets 11, 745–755

59. Hallil, M. A., Andrews, M. R., Sweet, M. J., and Fairlie, D. P. (2009) Histone deacetylase inhibitors in inflammatory disease. Curr. Top. Med. Chem. 9, 309–319

60. Marwick, J. A., Adcock, I. M., and Chung, K. F. (2010) Overcoming reduced glucocorticoid sensitivity in airway disease. Molecular mechanisms and therapeutic approaches. Drugs 70, 929–948

61. Hutt, D. M., Olsen, C. A., Vickers, C. J., Herman, D., Chalfant, M., Montero, A., Leman, L. J., Burke, R., Maryanoff, B. E., Balch, W. E., and Ghadiri, M. R. (2011) Potential agents for treating cystic fibrosis. Cyclic tetrapeptides that restore trafficking and activity of ΔF508-CFTR. ACS Med. Chem. Lett. 2, 703–707

62. Lu, J., Yang, C., Chen, M., Ye, D. Y., Lonser, R. R., Brady, R. O., and Zhuang, Z. (2011) Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. Proc. Natl. Acad. Sci. U.S.A. 108, 21200–21205

63. Hageman, J., van Waarde, M. A., Zylicz, A., Walerych, D., and Kampinga, H. H. (2011) The diverse members of the mammalian HSP70 machine show distinct chaperone-like activities. Biochem. J. 435, 127–142

64. Pipalia, N. H., Cosner, C. C., Huang, A., Chatterjee, A., Bourbon, P., Farley, N., Helquist, P., Wiest, O., and Maxwell, F. R. (2011) Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type CI mutant human fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 108, 5620–5625

65. Thomas, E. A., Coppola, G., Desplats, P. A., Tang, B., Soragni, E., Burnett, R., Gao, F., Fitzgerald, K. M., Borok, J. F., Herman, D., Geschwind, D. H., and Gottesfeld, J. M. (2008) The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington disease transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 105, 15564–15569

66. Chuang, D. M., Leng, Y., Marinova, Z., Kim, H. I., and Chiu, C. T. (2009) Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 32, 591–601

67. Zhang, L. J., Liu, X., Gafken, P. R., Kioussi, C., and Leid, M. (2009) A single ovulation upstream promoter transcription factor 1 (COUP-TFI) complex represses expression of the gene encoding tumor necrosis factor-α-induced protein 8 (TNFAIP8). J. Biol. Chem. 284, 6156–6168

68. Shi, Y., Sawada, J., Sui, G., Affar el, W., Whetstone, J. R., Lan, F., Ogawa, H., Luke, M. P., and Nakatani, Y. (2003) Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature 422, 735–738

69. Nakatani, Y., and Ogryzko, V. (2003) Histone deacetylase inhibitors. Methods Enzymol. 370, 430–444

70. Hathorn, T., Snyder-Keller, A., and Messer, A. (2011) Nicotinamide improves motor deficits and up-regulates PGC-1α and BDNF gene expression in a mouse model of Huntington disease. Neurobiol. Dis. 41, 43–50

71. Marks, P. A., and Dokmanovic, M. (2005) Histone deacetylase inhibitors. Discovery and development as anticancer agents. Expert Opin. Investig. Drugs 14, 1497–1511

72. Blander, G., and Guarente, L. (2004) The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 73, 417–435

73. Dokmanovic, M., Perez, G., Xu, W., Ngo, L., Clarke, C., Parmigiani, R. B., and Marks, P. A. (2007) Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol. Cancer Ther. 6, 2525–2534

74. Mielcarek, M., Benn, C. L., Franklin, S. A., Smith, D. L., Woodman, B., Marks, P. A., and Bates, G. P. (2011) SAHA decreases HDAC 2 and 4 and improves molecular phenotypes in the R6/2 mouse model of Huntington disease. Proc. Natl. Acad. Sci. U.S.A. 108, 1111–1118

75. Cameron, P. H., Chevet, E., Pluquet, O., Thomas, D. Y., and Bergeron, J. J. (2009) Calnexin phosphorylation attenuates the release of partially mis-
HDACi-Proteostasis Regulation of α1-Antitrypsin Deficiency

folded α1-antitrypsin to the secretory pathway. J. Biol. Chem. 284, 34570–34579
83. Nyfeler, B., Reiterer, V., Wendeler, M. W., Stefan, E., Zhang, B., Michnick, S. W., and Hauri, H. P. (2008) Identification of ERGIC-53 as an intracellular transport receptor of α1-antitrypsin. J. Cell Biol. 180, 705–712
84. Papp, E., Száraz, P., Korcsmáros, T., and Csermely, P. (2006) Changes of endoplasmic reticulum chaperone complexes, redox state, and impaired protein disulfide reductase activity in misfolding α1-antitrypsin transgenic mice. FASEB J. 20, 1018–1020
85. Graham, K. S., Le, A., and Sifers, R. N. (1990) Accumulation of the insoluble Piz-variant of human α1-antitrypsin within the hepatic endoplasmic reticulum does not elevate the steady-state level of grp78/BiP. J. Biol. Chem. 265, 20463–20468
86. Shen, Y., Ballar, P., and Fang, S. (2006) Ubiquitin ligase gp78 increases solubility and facilitates degradation of the Z-variant of α1-antitrypsin. J. Biol. Chem. 281, 17405–17412
87. Schmidt, B. Z., and Perlmutter, D. H. (2005) Grp78, Grp94, and Grp170 interact with α1-antitrypsin mutants that are retained in the endoplasmic reticulum. Am. J. Physiol. Gastrointest. Liver Physiol. 289, G444–G455
88. Norez, C., Noel, S., Wilke, M., Bijvelds, M., Jorna, H., Melin, P., Dejonge, M., and Beqç, F. (2006) Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the α-glucosidase inhibitor miglustat. FEBS Lett. 580, 2081–2086
89. Cormier, J. H., Tamura, T., Sunryd, J. C., and Hebert, D. N. (2009) EDEM1 recognition and delivery of misfolded proteins to the SELIL-containing ER complex. Mol. Cell 34, 627–633
90. Pan, S., Wang, S., Utama, B., Huang, L., Blok, N., Estes, M. K., Moremen, K. W., and Sifers, R. N. (2011) Golgi localization of ERMan1 defines spatial separation of the mammalian glycoprotein quality control system. Mol. Biol. Cell 22, 2810–2822
91. Marcus, N. Y., and Perlmutter, D. H. (2000) Glucosidase and mannosidase inhibitors mediate increased secretion of mutant α1-antitrypsin Z. J. Biol. Chem. 275, 1987–1992
92. Reiterer, V., Nyfeler, B., and Hauri, H. P. (2010) Role of the lectin VIP36 in post-ER quality control of human α1-antitrypsin. Traffic 11, 1044–1055
93. Cabral, C. M., Liu, Y., Moremen, K. W., and Sifers, R. N. (2002) Organizational diversity among distinct glycoprotein endoplasmic reticulum-associated degradation programs. Mol. Biol. Cell 13, 2639–2650
94. Hirao, K., Natsuka, Y., Tamura, T., Wada, I., Morito, D., Natsuka, S., Romero, P., Slten, B., Tremblay, L. O., Herscovics, A., Nagata, K., and Hosokawa, N. (2006) EDEM3, a soluble EDEM homolog, enhances glycoprotein endoplasmic reticulum-associated degradation and mannoside trimming. J. Biol. Chem. 281, 9650–9658
95. Christianson, J. C., Shaler, T. A., Tyler, R. E., and Kopito, R. R. (2008) OS-9 and GRP94 deliver mutant α1-antitrypsin to the Hrd1-SEL1L ubiquitin ligase complex for ERAD. Nat. Cell Biol. 10, 272–282
96. Burrows, J. A., Willis, L. K., and Perlmutter, D. H. (2000) Chemical chaperones mediate increased secretion of mutant α1-antitrypsin (α1-AT) Z. A potential pharmacological strategy for prevention of liver injury and emphysema in α1-AT deficiency. Proc. Natl. Acad. Sci. U.S.A. 97, 1796–1801
97. Aka, J. A., Kim, G. W., and Yang, X. J. (2011) K-acetylation and its enzymes. Overview and new developments. Handb. Exp. Pharmacol. 206, 1–12
98. Gnad, F., Ren, S., Choudhary, C., Fox, J., and Mann, M. (2010) Predicting post-translational lysine acetylation using support vector machines. Bioinformatics 26, 1666–1668
99. Galli, C., Bernasconi, R., Soldà, T., Calanca, V., and Molinari, M. (2011) Malecot participates in a backup glycoprotein quality control pathway in the mammalian ER. PLoS One 6, e16304
100. Hosokawa, N., Wada, I., Natsuka, Y., and Nagata, K. (2006) EDEM accelerates ERAD by preventing aberrant dimer formation of misfolded α1-antitrypsin. Genes Cells 11, 465–476
101. Oda, Y., Hosokawa, N., Wada, I., and Nagata, K. (2003) EDEM as an acceptor of terminally misfolded glycoproteins released from calnexin. Science 299, 1394–1397
102. Kahali, S., Sarcar, B., Prabhu, A., Seto, E., and Chinnaiyan, P. (2012) Class I histone deacetylases localize to the endoplasmic reticulum and modulate the unfolded protein response. FASEB J. 26, 2437–2445
103. Alam, S., Wang, J., Janciuksiene, S., and Mahadeva, R. (2012) Preventing and reversing the cellular consequences of Z α1-antitrypsin accumulation by targeting s4A. J. Hepatol. 57, 116–124
104. Hidvegi, T., Mukherjee, A., Ewing, M., Kemp, C., and Perlmutter, D. H. (2011) The role of autophagy in α1-antitrypsin deficiency. Methods Enzymol. 499, 33–54
105. Hidvegi, T., Ewing, M., Hale, P., Doppold, C., Beckett, C., Kemp, C., Maurice, N., Mukherjee, A., Goldbach, C., Atkins, S., Michalopoulos, G., and Perlmutter, D. H. (2010) An autophagy-enhancing drug promotes degradation of mutant α1-antitrypsin Z and reduces hepatic fibrosis. Science 329, 229–232
106. Kaushal, S., Annamali, M., Blomenkamp, K., Rudnick, D., Halloran, D., Brunt, E. M., and Teckman, J. H. (2010) Rapamycin reduces intrahepatic alpha-1-antitrypsin mutant Z protein polymers and liver injury in a mouse model. Exp. Biol. Med. (Maywood) 235, 700–709
107. Ogushi, F., Fells, G. A., Hubbard, R. C., Straus, S. D., and Crystal, R. G. (1987) Z-type α1-antitrypsin is less competent than M1-type α1-antitrypsin as an inhibitor of neutrophil elastase. J. Clin. Invest. 80, 1366–1374
108. Pan, S., Huang, L., McPherson, J., Muzny, D., Rouhani, F., Brantly, M., Gibbs, R., and Sifers, R. N. (2009) Single nucleotide polymorphism-mediated translational suppression of endoplasmic reticulum mannosidase I modifies the onset of end-stage liver disease in α1-antitrypsin deficiency. Hepatology 50, 275–281
109. Mast, S. W., Diekman, K., Karaveg, K., Davis, A., Sifers, R. N., and Moremen, K. W. (2005) Human EDEM2, a novel homolog of family 47 glycosidases, is involved in ER-associated degradation of glycoproteins. Glycobiology 15, 421–436
110. Gossai, S. J., Kwak, J. H., Luke, C. J., Long, O. S., King, D. E., Kovatch, K. J., Johnston, P. A., Shun, T. Y., Lazo, J. S., Perlmutter, D. H., Silverman, G. A., and Pak, S. C. (2010) Automated high-content live animal drug screening using C. elegans expressing the aggregation prone serpin α1-antitrypsin Z. PLoS One 5, e115460
111. Yi, C., Ma, M., Ran, L., Zheng, J., Tong, J., Zhu, J., Ma, C., Sun, Y., Zhang, S., Feng, W., Zhu, L., Le, Y., Gong, X., Yan, X., Hong, B., Jiang, F. J., Xie, Z., Miao, D., Deng, H., and Yu, L. (2012) Function and molecular mechanism of acetylation in autophagy regulation. Science 336, 474–477